Sugi Predict

Sugi Predict / Compounds / SCHEMBL616228

SCHEMBL616228

SCHEMBL616228

CC(C)(C)OC(=O)N1CCN(c2cnc(N)c(C(=O)O)n2)CC1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CKS1B P61024 2/20 0.60
▸ SKP1 P63208 2/20 0.60
▸ SKP2 Q13309 2/20 0.60
▸ MAP4K4 O95819 1/20 0.55
▸ PTPN11 Q06124 1/20 0.51
▸ GPR119 Q8TDV5 6/20 0.46
▸ ADK P55263 1/20 0.44
▸ SMARCA2 P51531 1/20 0.44
▸ SMARCA4 P51532 1/20 0.44
▸ PBRM1 Q86U86 1/20 0.44
▸ PIK3CA P42336 1/20 0.43
▸ ACHE P22303 1/20 0.43
▸ ATR Q13535 1/20 0.43
▸ LRRK2 Q5S007 1/20 0.42
▸ KIT P10721 1/20 0.42
▸ TBK1 Q9UHD2 1/20 0.42
▸ DDB1 Q16531 1/20 0.42
▸ CRBN Q96SW2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3186820 0.89 CKS1B (0.56) CKS1BSKP1SKP2MAP4K4PTPN11
SCHEMBL20046670 0.89 CKS1B (0.64) CKS1BSKP1SKP2MAP4K4PTPN11
SCHEMBL29521768 0.85 MAP4K4 (0.53) CKS1BSKP1SKP2MAP4K4PTPN11
SCHEMBL5757854 0.82 CKS1B (0.42) CKS1BSKP1SKP2MAP4K4PTPN11
SCHEMBL617637 0.80 GRM5 (0.57) CKS1BSKP1SKP2MAP4K4PTPN11
SCHEMBL20046669 0.80 CKS1B (0.58) CKS1BSKP1SKP2MAP4K4PTPN11
SCHEMBL1995627 0.79 CKS1B (0.57) CKS1BSKP1SKP2MAP4K4PTPN11
SCHEMBL30512314 0.79 CKS1B (0.57) CKS1BSKP1SKP2MAP4K4PTPN11
SCHEMBL27148195 0.78 MAP4K4 (0.55) CKS1BSKP1SKP2MAP4K4PTPN11
SCHEMBL876797 0.78 CKS1B (0.59) CKS1BSKP1SKP2MAP4K4PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220362396-A1 AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2022-11-17 — — US disclosed
US-20220362396-A1 AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2022-11-17 — — US disclosed
WO-2021102332-A1 TGFBETAR2 INHIBITOR-LRRC15 ANTIBODY CONJUGATES AND USES THEREOF SILVERBACK THERAPEUTICS, INC. (US) 2021-05-27 — — WO disclosed
WO-2021102332-A1 TGFBETAR2 INHIBITOR-LRRC15 ANTIBODY CONJUGATES AND USES THEREOF SILVERBACK THERAPEUTICS, INC. (US) 2021-05-27 — — WO disclosed
EP-3802518-A1 AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF Silverback Therapeutics, Inc. (US) 2021-04-14 — — EP disclosed
US-20140113005-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-04-24 — — US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 — — US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 — — US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 — — US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 — — US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 — — US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 — — US disclosed
EP-2370424-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2011-10-05 — — EP disclosed
WO-2010054398-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-14 — — WO disclosed
WO-2010054398-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-14 — — WO disclosed
US-7674791-B2 Triazolopyrazines and methods of making and using the same BIOGEN IDEC MA INC. (US) 2010-03-09 — — US disclosed
US-20070010520-A1 Triazolopyrazines and methods of making and using the same BIOGEN IDEC MA INC. 2007-01-11 — — US disclosed
EP-1615931-A1 TRIAZOLOPYRAZINES AND METHODS OF MAKING AND USING THE SAME Biogen Idec MA Inc. (US) 2006-01-18 — — EP disclosed
WO-2004092177-A1 TRIAZOLOPYRAZINES AND METHODS OF MAKING AND USING THE SAME BIOGEN IDEC MA INC. (US) 2004-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140113005-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 CKS1B 117/4885SKP1 171/4885SKP2 156/4885
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 CKS1B 117/4885SKP1 171/4885SKP2 156/4885
US-20070010520-A1 Triazolopyrazines and methods of making and using the same ADORA2A, ADORA3, ADORA1 CKS1B 1166/4885SKP1 1175/4885SKP2 831/4885
US-20220362396-A1 AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF TGFBR2, SMAD2, ACVR2A CKS1B 3530/4885SKP1 3937/4885SKP2 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.